Excellent
Fully Aligned
Patient Risk:
Low
Summary
The AI claim that hepatotoxicity and embryofetal (fetal) toxicity are supported by the AUBAGIO FDA label is consistent with the provided label text in Warnings and Precautions (5.1, 5.2), Contraindications (4), and Use in Specific Populations (8.1).
Category Scores
Accurate Statements
Hepatotoxicity and Embryofetal (fetal) toxicity are supported by the FDA label for AUBAGIO (teriflunomide).
Supported by Warnings and Precautions 5.1 (Hepatotoxicity) and 5.2 (Embryofetal Toxicity), plus Contraindications 4 (pregnancy/reproductive potential contraception, severe hepatic impairment) and Use in Specific Populations 8.1 (Pregnancy).
Hepatotoxicity (Warnings 5.1): clinically significant and potentially life-threatening liver injury is reported; patients with pre-existing liver disease or taking other hepatotoxic drugs may be at increased risk; patients with pre-existing liver disease or ALT >2x ULN should not normally be treated; contraindicated in severe hepatic impairment; monitoring and management/elimination procedures are described if injury is suspected.
Consistent with label text in 5.1.
Embryofetal (fetal) toxicity (Warnings 5.2): AUBAGIO may cause fetal harm; teratogenicity/embryofetal lethality in animals; contraindicated in pregnant women and in females of reproductive potential not using effective contraception; if pregnancy occurs, stop treatment and perform accelerated elimination with target plasma concentration <0.02 mg/L.
Consistent with label text in 5.2 and related Contraindications 4 and accelerated elimination in 5.3.
Embryofetal (fetal) toxicity contraindication language: AUBAGIO is contraindicated in pregnant women and in females of reproductive potential not using effective contraception due to potential fetal harm.
Consistent with Contraindications 4.
Pregnancy section reiteration/management: accelerated elimination may decrease fetal risk and includes verification of plasma teriflunomide concentration <0.02 mg/L.
Consistent with Use in Specific Populations 8.1 (Pregnancy).
Unsupported Statements
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
The evaluated response makes a high-level accuracy claim about label-supported warnings (hepatotoxicity and embryofetal toxicity) without providing dosing advice or incorrect safety instructions.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Fully Aligned
Primary Issue
Suggested Improvement